Table 3: Pretreatment and posttreatment clinical characteristics of type 2 diabetes patients with hypertriglyceridemia treated with fenofibrate.

ParametersPretreatment
()
Posttreatment
()
P value

BMI (kg/m2)26.46 ± 4.6026.37 ± 4.590.209
SBP (mmHg)125.00 ± 7.56125.48 ± 6.760.668
DBP (mmHg)74.24 ± 8.7473.92 ± 7.300.831
FBG (mmol/L)7.42 ± 1.017.32 ± 1.000.215
TC (mmol/L)4.62 ± 0.664.83 ± 0.690.145
HDL (mmol/L)1.25 ± 0.291.47 ± 0.27<0.001
LDL (mmol/L)2.80 ± 0.532.82 ± 0.660.845
TG (mmol/L)3.05 ± 0.861.84 ± 0.76<0.001
AST (U/L)22.08 ± 7.3323.84 ± 9.040.322
ALT (U/L)26.00 ± 5.6924.44 ± 11.640.518
CR (μmol/L)71.92 ± 13.7476.10 ± 17.290.164
CK (U/L)84.64 ± 27.6991.20 ± 37.280.307

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CR, creatinine; CK, creatine kinase.